

Index

Note: Drugs are listed under their generic names.

- abdominal pain, 63–66, 77–78, 140
- activity
 - effects of, 233–34, 237
 - increasing, 174
 - managing, 160–62
 - reduced, 52–53, 99, 100, 181, 205
 - symptoms and, 167–69, 181
 - See also* energy
- acupuncture, 79, 190
- age, 56, 61
- AIDS. *See* HIV/AIDS
- alcohol, 130–31
- alexithymia, 107
- allergies, 42
 - See also* multiple chemical sensitivity (MCS)
- alosetron (Lotronex), 140
- alternative therapies, 4
 - complementary therapies *vs.*, 159, 211–14
 - evaluating, 214–17, 225–26
 - for pain, 190–91
 - research on, 219–20
 - turned to in frustration, 3, 15–16, 94, 186–87, 213, 221
- Alzheimer's, 40
- Ambrotose, 188, 222
- Amish, FM rates among, 61
- amitriptylene (Elavil), 150, 156
- amphetamines, 132–33, 145
- Ampligen, 147
- anemia, 25–26, 31
- anesthetic injections, 152–53
- antibiotics, 28, 245–46
- antibodies, 26, 34–35, 36–38, 228–29
- anxiety, 106, 120–21
 - effects of, 100–101, 168
 - medicines for, 108–15, 151
 - symptoms of, 108, 243
 - treatments for, 83–84, 115–17
- anxiety disorder, 69–70
- appetite loss, 100
- aquatics class, 175
- aspartame, 42–43
- Atabrine, 154
- attention/concentration, 40–41, 53
 - See also* cognitive problems
- autism, diagnosis of, 46
- autoimmune illnesses, 42–43, 146
 - FM or CFS and, 153–54
 - gender and, 30, 33–34
 - MS as, 33–34
 - myositis, 31
 - Sjögren's as, 32–33
 - tests for, 26, 29–30, 32–33
- autonomic nervous system (ANS)
 - brain function and, 240–41
 - breathing and, 198–200, 241–42
 - IBS and, 140–41
 - influences on, 124–25, 199–201, 249
 - stress and, 122–25, 198–200
- back pain, 62, 175
- balance, 191–95
- barium enema, 42
- Beck, Aaron, 116
- Bell, David, 217–18, 248
- benign monoclonal gammopathy (BMG), 35
- Benson, Herbert, 126, 201

- benzodiazepines, 108–9, 157
 Bextra, 148
 BioBran, 222–23, 229, 234
 biofeedback, 126–27, 199–200, 242
 blood, 236, 243
 disorders of, 34–35
 volume of, 244–45, 247
 blood pressure, 126, 196–98
 fatigue and, 58–59, 135
 high, 135
 influences on, 114, 198, 240–41
 low, 135, 195–96
 bowel problems, 63–66, 77–78, 140, 206
 brain, 17, 236, 250–51
 blood flow to, 243–44
 CFS and, 102–3, 237–38
 chemistry of, 156–57, 188
 depression and, 102–3, 108–15
 multiple sclerosis and, 33–34
 narcolepsy and, 132–33
 responses to stress in, 122–23
 brain fog, 40
 medicines and, 151–52, 158
 See also cognitive problems
 brain function
 effects of massage on, 193–94
 problems in, 41, 237–39
 stress and, 239–41
 tests of, 40–41, 191–92, 237–41
 breathing
 POTS and, 196–98
 relation to heart rate, 241–42
 retraining, 126–27, 198–203
 sleep-disturbed, 134–37
 Buspar, 108–9

 caffeine, 130–31, 141
 carbohydrates, 205–6
 carnitine, 188
 Celebrex, 148
 celiac disease, 42
 CFS-like illness, 55–56
 chelation therapy, 218–19
 chiropractic treatment, 194
 chlamydia pneumoniae, 39
 chronic fatigue and immune dysfunction syndrome (CFIDS), 233
 chronic fatigue syndrome (CFS)
 consistency of symptoms in, 65, 160–61
 definitions of, 18, 52, 100–101
 depression and, 56–57, 97, 99–103
 diagnosis of, 1–2, 70, 141, 191–92, 229–30
 drugs for, 142–45
 effects of, 40, 192, 236, 242
 immune system and, 222–23, 234–36
 incidence of, 56, 59
 in kids *vs.* adults, 196, 242–43
 onset of, 57–58, 69
 other syndromes and, 62, 68–70
 POTS and POSH and, 196–98, 242–45
 proposed causes of, 29, 218–19, 229, 231, 237–41, 245
 relation to atypical depression, 113–14, 145
 research on, 59, 142, 157–58, 231
 rheumatological components of, 153–54
 risk factors for, 57–59, 118
 sleep problems and, 136, 158, 234–36
 somatization disorder diagnosis, 48, 50
 stress and, 119, 241
 symptoms in, 53, 65, 119
 tests for, 29
 treatments for, 83, 155, 185, 188–90, 217–18, 221–23
 triggers for, 57
 clonazepam (Klonopin), 157
 codeine, 134
 cognitive-behavioral therapy (CBT), 116–17, 170, 181–82
 cognitive problems, 67, 107, 144
 causes of, 100, 119, 236, 241
 in CFS, 53, 57, 237–39
 depression and, 57, 99, 237–38
 immune system and, 234, 236
 neuropsychological tests for, 40–41
 cold sores, 37
 Collins, Jim, 195
 communication, doctor-patient, 43
 about emotional distress, 106–7
 in diagnosis process, 50
 factors in poor, 14–15
 females better at, 82–83
 importance of, 3, 94
 poor, 14–15, 50
 relationship and, 10–13, 79–80

- communication, primary doctor-specialists, 89–90
- complementary therapies
 alternative treatments *vs.*, 211–13
 for CFS, 189–90
 research on, 219–20
 rules for trying, 185–86
See also alternative therapies
- complete blood count (CBC), 25
- COMT, 232
- constitutional fatigue, 52
- contagiousness, of CFS, 59
- control, 3, 214
 increasing, 177, 180, 204–6, 208
 overcoming helplessness, 172, 175
- cortisol levels, 240–41
- costs, 200
 of alternative therapies, 212–13, 215–17
 of antidepressants, 205, 249
 of medicines, 156, 252
 of neuropsychological tests, 41
 of nutraceuticals, 189, 225–26
- counseling. *See* psychotherapy
- Cousins, Norman, 178–79
- Cox-2 inhibitors, 148
- creatine phosphokinase (CPK), 30–31
- CT scan, 39
- cyclobenzaprine (Flexeril), 150
- Cymbalta, 251
- cytokines, 100, 119, 233–36
- deconditioning, 168–69, 180–81
- dehydroepiandrosterone (DHEA), 189
- delayed sleep phase disorder, 133
- dentists, 62–63, 78, 136–37
- depression, 71
 atypical, 113–14, 145
 chronic fatigue syndrome and, 56–57, 97, 99–100, 103
 definition of, 98–99
 diagnosis of, 46, 100
 drugs for, 108–15, 145–46, 148–49, 248–49
 effects of, 3, 98–99, 103, 122, 168, 237, 243
 fatigue and, 56–57, 231
 genetic component of, 231–32
 intensifying other symptoms, 3, 103, 111, 117, 149
 onset of, 57
 overlapping syndromes and, 69–70
 pain and, 105, 112, 231
 patient not telling doctors about, 106–7
 quantifying, 103–5
 stress *vs.*, 122
 treatments for, 111, 115–17, 187, 189, 249–51
 unexplained medical symptoms and, 105–7
 variations of, 100–103
- desipramine (Norpramin), 150
- diagnosis, 68, 88, 138
 of chronic fatigue syndrome, 51–53
 of depression, 98, 100, 110
 effects of, 16, 48–49
 effects of drug discoveries on, 16–17, 229–30
 of fibromyalgia, 60–61, 231–32
 of IBS, 64–65
 lack of, 1–3, 16–17, 19–20, 23, 43–44
 of MCS, 67
 of migraines, 46
 process for coming to, 3, 10, 13, 22–24, 55–56, 70–71
 symptoms in, 8–9, 26–27
 treatment and, 26–27, 75
- diazepam (Valium), 150–51, 157
- digestion, 198, 240–41
- doctors
 allowing patients to fall through cracks, 15–16, 21, 26–27, 90–92
 alternative therapies and, 214–15
 criteria for choosing, 20–22, 84, 93–94
 desire for explainable medical symptoms, 15, 48, 60, 105–6
 diagnosis process of, 3, 10, 13, 22–24, 28, 55–56, 70–71
 effects of managed care on, 82, 84
 explanations by, 3, 10, 25, 31, 43
 family practice *vs.* specialists, 20
 finding female, 20–21, 93
 getting second opinions from, 73–75
 importance of primary care, 79–81, 89–90, 93, 152
 labeling of patients by, 15, 48–49
 lack of skill with depression, 98, 111

- doctors (*continued*)
 limitations of, 68, 138
 prescription process of, 109–10,
 153–54
 rates of visiting, 56, 66, 103–5
 relationship with, 1–2, 18, 79–81,
 110, 170–71, 210–11, 213–14,
 216–17
 response to not knowing, 19–20, 23,
 43–44
 responsibilities of, 15–16, 90–93
 role of, 18–19, 33, 138–39, 213
 shopping for, 3, 15, 19, 81–82
 somatization disorder diagnosis by,
 50–51
 tertiary-care, 110
See also communication
- doctor training, 11, 13
 in diagnosis, 138
 focus of, 10, 19–20, 105–6, 210–11
 on “hard patients,” 16, 19–20
 integrative approach and, 86–87, 170
 “dropsy,” 16
- duloxetine (Cymbalta), 112, 148–49,
 205
- Eades, Michael R., and Mary Dan, 208
- echinacea, 220
- education levels, 62
- Ellis, Albert, 116
- emotional distress, 106–7
See also anxiety; depression
- endorphins, 125
- Enerdyn (propionyl carnitine), 188
- energy
 budgeting, 162–67, 172–73, 181–82
 building, 160, 166, 172–81
 conserving, 160, 164
 creating reserve of, 172–73, 180
 monitoring use of, 161–63
- Engel, George, 86–87
- envelope theory, of energy budgeting,
 161–66, 172–81
- epilepsy, 249–51
- Epstein-Barr virus (EBV), 36–38,
 228–29
- Epworth Sleepiness Score, 128
- erythropoietin, 248
- escitalopram (Lexapro), 112
- eszopiclone (Lunesta), 156
- evening primrose oil, 189
- exercise, 3, 246
 choices of, 175, 194–95
 combining with diet, 205, 208
 effects of, 124–25, 247
 lack of, 168–69
See also walking
- eyes and vision, 32–34, 154
- face pain, 62–63, 78
- Facing and Fighting Fatigue* (Natelson),
 93–94
- fainting, 195–96
- family practitioners, 20, 74
See also doctors
- fatigue
 activity levels and, 57, 167–68
 blood pressure and, 58–59, 135
 in definition of severe chronic fatigue
 syndrome, 100–101
 depression and, 97, 99, 231
 drugs for, 110–11, 134, 141–47, 158,
 214–15, 223–24, 248–49, 251–52
 Epstein-Barr virus and, 36–38,
 228–29
 evaluation of, 51–53
 explanations for, 9–10
 fibromyalgia and, 62, 134
 genetic component of, 231
 immune system and, 34–35, 228–29,
 232–36
 infections and, 35–36, 39, 75–76
 mononucleosis and, 35–36, 228–29
 multiple chemical sensitivity and,
 67–68
 pain and, 119–20, 231
 in Persian Gulf war veterans, 14
 proposed causes of, 32–33, 36–39,
 55–56, 58–59, 100, 119, 131,
 133–35, 191, 241, 252
 risk factors for, 58–59, 68, 168
 sleep problems and, 128–29, 135,
 248
 stress and, 118–21, 137
 as symptom, 24–25, 38, 99, 106–7,
 245
 tests for causes of, 25–32
 treatments for, 158, 173, 190, 201–3,
 221–22, 248
See also chronic fatigue syndrome

- fentanyl transdermal (Duragesic), 152
 fever, 29, 53–55, 75–76
 Fibrinol, 223–25
 fibromyalgia (FM)
 diagnosis of, 1–2, 50, 70–71, 77, 141
 drugs for, 134, 150–52, 158, 252
 genetic component of, 231–32
 not visiting doctor for, 103–5
 onset of, 241
 overlap with other syndromes, 62–63,
 68–70, 101
 pain management in, 134, 148,
 190–91, 250–52
 primary and secondary, 60
 proposed causes of, 30, 33, 69, 136,
 157–58, 218–19, 233, 245
 rheumatological component of, 30,
 77, 153–54
 risk factors for, 61–62
 sleep disorders and, 129, 137, 157–58
 symptoms of, 65, 103, 251
 as syndrome, 17–18
 treatments for, 154–55, 175, 177,
 185, 200, 223–24
 “fight or flight” response, 123–24,
 240–41, 249
 flare-ups, 161, 165–66, 167
 flulike illness, 24, 35–36, 38–39, 57, 59
 fluoxetine (Prozac), 109, 111
 food, and MAOIs, 114–15
 food poisoning, 64
 Freeze-Framer, 200, 242
 functional illness, 141
 functional somatic distress, 70

 gabapentin (Neurontin), 134, 151
 gamma globulin, 146–47
 gastroenterologists, 77–78
 gender, 55, 134
 autoimmune illness and, 30, 33–34
 doctors and, 8, 14–15, 20–21, 47,
 82–83
 incidence of diseases and, 30, 33,
 61–62, 64, 132–33
 suicide and depression and, 97–98
 genetics, 45–46, 230–32
 Glaser, Ron, 38
 gluten enteropathy, 42
 growth hormone, 154–55
 guilt and worthlessness, 99, 102

 gut, diseases of, 42

 Hashimoto’s thyroiditis, 30, 33
 headaches, 54–55, 122–23, 150, 190
 heart problems, 135, 242, 245
 heart rate
 breathing and, 198–200, 241–42
 POTS and, 196–98, 242–45
 stress and, 123, 240–41
 walking and, 179–80
 heavy metals, 218–19
 hepatitis C, 28, 252
 herpes viruses, 35, 37–38, 41
 history, in diagnosis, 23
 HIV/AIDS, 28, 37, 138–39
 HMOs, 74–75
 hormones, 27, 240–41, 248
 humor, 178–79
 hydrocortisone, 146
 hydroxychloroquin (Plaquenil), 154
 hyperventilation, 197–98, 243
 hypnosis, 79, 190
 “hypochondriacs,” 15
 hysteria, 49–50

 idiopathic chronic fatigue (ICF), 52, 56,
 70, 99
 illness, *vs.* disease, 9
 immunoglobulin deficiencies, 34–35
 immune system, 38, 222–23
 in chronic pain and fatigue, 232–36
 dysregulation in, 37, 146–47
 response, 99–100, 119
 immunoelectrophoresis (IEP), 34–35
 infections
 CFS and, 57, 75–76, 245–46
 effects of, 27, 35, 99–100, 140, 241
 GI, 64, 69
 herpes viruses and, 35, 37
 immune system and, 34–35, 222–23
 repeated, 34–35, 37, 147
 tests for, 27, 38–40
 as trigger, 57, 75–76, 168
 infectious disease specialists, 39, 75–76
 inflammatory bowel diseases, 42
 insurance, 40, 74–75, 81, 127, 145,
 194, 249
 integrative/biopsychosocial approach,
 86–87, 89
 interferon-alpha, 155

- Internet, 2, 11, 116
internists, 74–75
iron deficiency, 134
irritable bowel syndrome (IBS), 18,
77–78, 190
 diagnosis of, 71, 141
 drugs for, 140–41, 158
 proposed causes, 69, 135–36, 218–19
 symptoms of, 63–66, 239
 tests for, 41–43
- Jason, Lenny, 161, 165
jaw, tension in, 122
Jobst support stockings, 247
joints, 60, 63, 154
 pain in, 39, 76–77, 148, 175, 191
 treatments for, 148, 154, 175
- labeling, of patients, 7, 15
lactose intolerance, 42
lamotrigine (Lamictal), 151–52
Lange, Gudrun, 250–51
Lehrer, Paul, 200
ligaments, 30, 60, 79, 150
listening, 11, 13, 19–20
liver dysfunctions, 27–28
living food diet, 204
Low, Abraham, 116
lupus. *See* autoimmune illnesses; sys-
temic lupus erythematosus (SLE)
Lyme disease, 27–28, 57
lymph glands, enlargement of, 35,
54–55, 72–73, 75–76
- magnesium injections, 189
managed care, effects of, 82, 84
mantras, 178–79, 201–2
massage, 190–94
medical attention, 7–8, 56, 66, 103–5
medical materialism, 44–46
medical records, 90
medicine, allopathic, 185, 242
 as based on science, 50–51
 high-tech approaches in, 210–11
 progress in, 46, 50–51
 See also doctors
medicines
 addictiveness of, 142, 144–45,
 150–52, 156–57
 antibiotics, 28, 245–46
 antidepressants, 112, 156–57
 antidepressants for fatigue, 110–11,
 145–46
 antidepressants for pain, 110,
 148–49, 249
 antiepileptics, 151–52, 249
 antimalarial, 154
 anti-Parkinson's, 134, 145
 antiviral, 138–39
 approval process for, 185, 187, 189,
 212
 costs of, 156, 205, 249, 252
 cytokines as, 233
 for depression and anxiety, 108–15
 development of, 149, 158–59, 210,
 251–52
 discontinuing, 148, 186
 effects of, 138–40
 for fatigue, 141–47, 251–52
 for fibromyalgia, 148–49
 for IBS, 78, 140–41
 to increase blood volume, 247–48
 MAOIs as antidepressants, 113–15,
 145–46
 multiple uses for, 150
 NSAIDs, for chronic pain, 147–48
 nutraceuticals as, 187–90
 for pain, 79, 89, 147–54, 149, 251–52
 patients not taking, 12–13, 186
 recognition of diseases and, 18,
 140–41, 149, 157
 for restless legs syndrome, 134
 rheumatological, 153–54
 side effects of, 12–13, 158–59
 for sleep problems, 132–33, 155–58,
 248
 steroids, 146, 153–54
 stimulants for fatigue, 142, 144
 testing of, 142–43, 185, 187, 189,
 220, 229–30, 251
 thyroid replacement, 217
 transdermal, 146, 153
 in treatment plan, 75, 116–17
 for unexplained illnesses, 252
meditation, 125–26, 201
melatonin, 155–56
methadone, 152
methylphenidate (Ritalin), 133, 144–45
migraine headaches, 17–18, 46,
199–200, 250

- milnacipran, 251
 modafinil (Provigil), 132–33, 142–44, 158, 214–15
 monoamine oxidase inhibitors (MAOIs), 113–15, 145–46
 mononucleosis, 35
 acute *vs.* chronic, 36, 228–29
 relation to CFS, 36, 57, 69, 72
 mouth
 dry, 32–33, 122–23
 pain in, 62–63
 MRI (brain magnetic resonance imaging), 34, 41
 MS-Contin, 152
 multiple chemical sensitivity (MCS), 66–68, 71, 218–19
 multiple myeloma, 35
 multiple sclerosis (MS), 33–34, 41, 101, 236
 muscle aching, 76–77
 causes of, 30–31, 57, 100, 119, 130
 treatments for, 155, 177
 muscle pain, 30–31
 treatments for, 79, 146, 148, 154, 191
 muscle relaxants, 150
 muscles, 63, 79, 246
 chemistry of, 30–31, 188
 FM and, 60, 150, 246
 relaxation of, 125–26
 stress and, 122–26, 124
 torsion dystonia of, 45–46
 muscle weakness, 31, 34, 53–54
 myositis, 31

 narcolepsy, 132–33, 141
 Natelson diet, 204–9
 Natelson Six-Week Rule, 148, 186, 189, 190, 214–15
 National Center for Complementary and Alternative Medicine (NCCAM), 219–20
 natural killer (NK) cells, 222–23, 234
 nausea, 155, 252
 neck, pain in, 122–23
 nerves, latent viruses in, 37
 nervous system, 34, 191, 195
 See also autonomic nervous system (ANS)
 neurogenic hypotension, 195–96
 neuropsychological tests, 29, 40–41, 49
 nicotine, 130–31
 norepinephrine, 112–13, 149
 nortryptilene (Pamelor), 150
 NSAIDs, 147–48
 numbness, 34
 nutraceuticals, 187–90, 220–26
 nutrition, 134, 203–9
 nutritional supplements
 with diets, 204, 208
 evaluating claims of, 225–26
 intravenous, 217–19
 uses of, 134, 141–42, 186–87

 odors, in MCS, 67
 ondansetron (Zofran), 252
 opiates, 152
 orthostatic intolerance, 244, 247–48
 See also postural orthostatic syndrome of hyperventilation (POSH);
 postural orthostatic tachycardia syndrome (POTS)
 oxycarbazepine (Trileptal), 152
 oxycodone (Percocet), 152

 pain
 abdominal, 63–66, 77–78, 140
 activity and, 167–68
 chronic, 78–79, 147–54, 221–22, 232–36
 depression and, 97, 105, 112, 231
 drugs for, 75, 110, 112, 134, 147–54, 158, 249, 251–52
 explanations for, 10, 60
 fibromyalgia and, 60–63, 77, 134, 231–32, 238–39, 251
 immune system and, 34–35, 232–36
 isolated, 62–63, 77–78
 levels of, 63, 69
 in mouth and face, 62–63, 78
 multiple chemical sensitivity and, 68
 in muscles and joints, 30–31, 39, 59–60, 76–77
 onset of, 59
 risk factors for, 68, 168
 sensitivity to, 232, 238–39, 251
 specialists treating, 59–60, 76–77, 89
 stress and, 118–20, 137
 as symptom, 28, 106–7, 231
 tests for causes of, 25–32

- pain (*continued*)
 treatments for, 75, 89, 177, 190–91, 193–94, 200, 221–24, 250
 widespread, 59, 60–63, 105, 147–54, 231–32
- pain management centers, 77–79, 89, 182
- parvovirus B19, test for, 38–39
- pedometer, 161–62, 173, 175–79
- Persian Gulf war veterans, 14, 59
- personality, 48–49, 66, 101, 168
- personal trainers, 181
- pessimism, and IBS, 168
- physical exam, in diagnosis, 23
- physical therapists, 181, 194
- polycythemia, 25–26
- polymerase chain reaction (PCR) test, 37–38, 41
- positive thoughts, focusing on, 171–72, 177–78, 181
- postural orthostatic syndrome of hyperventilation (POSH), 197–98, 242–45, 247
- postural orthostatic tachycardia syndrome (POTS), 196–98, 217–18, 242–45, 247
- poverty, 8, 62
- pramipexole (Mirapex), 134
- pregabalin (Lyrica), 151
- psychiatric disorders, 20, 46–50, 55–56, 107
- psychiatrists, 98–100, 102, 112, 114
- psychoanalysis, 46
- psychological factors, 16–17, 66, 69, 86–87
- psychotherapy, 79, 115–17, 126–27, 216–17
- quality of life, 53, 66, 69, 87, 103, 170, 174, 180
- race/ethnicity, 56, 64, 130
- ramelteon (Rozerem), 156
- Raphael, Karen, 63, 105, 231
- rash, parvovirus B19 causing, 39
- Recovery Inc., 116
- relationships, 87, 163–65
- relaxation, 201–3
- Relaxation Response, 125–26
- research, 69–70
 basic *vs.* clinical, 229–30
 on CFS, 59, 142, 157–58
 design of, 51, 142–43, 224–25, 230–32
 on drugs, 109–10, 142, 149, 214–15, 251–52
 on fatigue *vs.* sleepiness, 128–29
 on IBS, 135–36
 on immune system, 232–36, 233
 importance of participating in, 84–85, 230
 on medically unexplained symptoms, 45–47, 105–6, 230–36, 244–45, 252
 on nutraceuticals, 187–89, 226
 on nutrition, 204, 218
 on overlapping syndromes, 68–70
 on POTS, 196–98
 process for, 227–28, 235, 246, 250
 serendipity in, 249–50
 on treatments, 154–55, 192–94, 219–20, 227–30, 247–48
See also medicines
- resiliency, 174
- restless legs syndrome (RLS), 133–34
- rheumatoid arthritis (RA), 101, 204, 231
 fibromyalgia and, 30, 60
 tests for, 29–30, 77
See also autoimmune illnesses
- rheumatological diseases, 60–61, 204
See also autoimmune illnesses
- rheumatologists, 30, 59–60, 76–77
- Rolfing. *See* massage
- Rome II criteria, for IBS, 65
- sadness, 106–7
- SAMe (S-Adenosyl-Methionine), 189
- schizophrenia, 17, 46–47
- second opinions, 73–75
- sedatives, for sleep problems, 156–57
- selective serotonin reuptake inhibitors (SSRIs), 108, 111–13, 204–5
- selegeline (Eldepryl, for oral use), 145–46, 248–49
- selegeline (Emsam, in patch form), 146
- serotonin, 140–41, 156–57
 in depression, 102, 111–12
 drugs and, 149, 252

- serotonin/norepinephrine reuptake inhibitors (SNRIs), 149
- serum protein electrophoresis (SPEP), 34–35
- Shanahoff-Khalsa, David, 201
- Siberian ginseng, 221–22
- sicca (dry eyes and mouth), 32–33
- sick building syndrome, 67
- signs, disease, 8, 9, 24, 27
- sinusitis, 39
- Sjögren's Syndrome/Disease, 32–33
- sleep disorders, 128, 131–37, 142, 157–58
- sleep problems, 3, 204
 - causes of, 29, 100, 120, 127–31, 135–36
 - in CFS, 53–55, 57, 62
 - cytokines and, 100, 234–36
 - depression and, 57, 99, 113
 - drugs for, 112, 155–58, 248
 - effects of, 130, 157
 - excessive, 34, 41, 113
 - in FM, 53–55
 - immune system and, 234–35
 - stress and, 120, 122–23
- sodium oxalate (Xyrem), 157
- somatization disorder (SD), 47–51
- somatizers, 15, 69
- sore throat, 35–36, 54–55, 75–76
- specialists, 89
 - cardiologists, 242
 - choosing, 80–87, 93–94
 - in environmental medicine, 67
 - first visit to, 87–90
 - following through with, 12–13
 - gastroenterologist, 42, 77–78
 - getting second opinion from, 74–75
 - hematologists, 35
 - infectious diseases, 39, 59, 75–76
 - internists, 74–75
 - limitations of using, 68, 88
 - nutritionists, 204
 - pain management, 77–79, 89, 158
 - primary care doctors and, 79–81, 89–90
 - rheumatologists, 59–60, 76–77, 153
 - sleep medicine, 128–29
 - tertiary-care doctors, 110
- spinal cord, 33
- spinal fluid, 41, 236–38
- St. John's wort, 187
- steroids, 146, 153–54
- stimulants, 142, 144
- stomach, 122–23
- stress, 49, 108, 137, 140
 - effects of, 37, 118–23, 130, 198–200, 239–41
 - in integrative/biopsychosocial approach, 86–87
 - treatments for, 120–21, 123–27, 194–95, 200–201
 - unexplained symptoms as, 119–20, 123
- structural integration. *See* massage
- suicide, 98, 102
- symptoms
 - consistency of, 65–66, 160–61
 - copied with, 168, 170–72
 - depression intensifying, 3, 103, 111, 117, 149
 - in diagnosis process, 23–24, 26–27, 47, 49–50
 - explanations for, 8–10, 15
 - influences on, 118–19, 168–69, 173
 - multiple, 14–15, 68–70, 88–89
 - in overlapping syndromes, 68–70
 - personal responses to, 7–9, 13–14
 - prevalence of unexplained, 105–7
 - signs *vs.*, 9, 24
 - in syndromes, 17, 46–47, 49–50
 - See also* specific symptoms and disorders
- syndromes, 17–18, 46–47, 49–50
- systemic lupus erythematosus (SLE), 29–30, 30, 60–61, 77, 153
- tai chi, 194–95
- teeth, and face pain, 62
- tegaserod (Zelnorm), 140
- temazepam (Restoril), 157
- temperature, elevated. *See* fever
- temporomandibular disorder (TMD), 63, 78, 122, 232, 241
- tenderness, 122
 - in FM, 60–61, 231–32
 - treatments for, 152–53, 155
- tests, 10, 24
 - for balance, 192
 - blood, 32–33
 - for blood disorders, 34–35

- tests (*continued*)
- for celiac disease, 42
 - for chlamydia pneumoniae, 39
 - CT scan, 39
 - doctors' responses to, 19–20, 25, 44
 - Epworth Sleepiness Score, 128
 - explanation of results from, 31, 43
 - for hyperventilation, 197–98
 - for IBS, 41–43
 - for infections, 38, 39–40, 76
 - lacking, 47, 64, 70, 140–41
 - limitations of, 43–46
 - MRI, 34, 237–38
 - neuropsychological, 40–41, 49, 237–39
 - for pain and fatigue, 25–32
 - for parvovirus B19, 38–39
 - PCR, 37–38
 - results from, 43–44, 90
 - for rheumatological diseases, 153
 - skin, 38
 - sleep studies, 128–29, 137, 235
 - specialists ordering, 76, 77–78
 - of spinal fluid, 41
- therapeutic alliance, 152
- thyroid dysfunction, 27, 30–31
- thyroid pills, 217
- tizanidine (Zanaflex), 151
- topiramate (Topamax), 152
- torpor, in atypical depression, 113
- torsion dystonia, 17, 45–46
- tramadol (Ultram), 151
- trauma, in FM risk factors, 62
- treatments and treatment plans
- avoiding harmful, 210, 214
 - belief in, 161, 175, 181–82
 - compliance with, 12–13
 - components of, 116–17, 170, 205, 208
 - danger of do-it-yourself approaches, 211, 214–15
 - diagnosis and, 26–27, 43, 75
 - drug developments and, 158–59, 229–30
 - energy management in, 160–63
 - exercise in, 169, 180
 - lack of, 1–3, 185
 - nutrition in, 203–9, 217–19
 - placebo effects in, 216–17
 - research into new, 227–30
- VNS in, 249–51
- wellness work in, 178–79, 181–82, 213–14
- See also* alternative therapies; complementary therapies; medicines; specific symptoms and disorders
- tricyclic antidepressants (TCAs), 108–10, 149–50, 204–5
- tropisetron, 155, 252
- tryptophan, 155–56
- tuberculosis (TB), 38
- upper airway resistance syndrome (UARS), 135–36
- vagal nerve stimulation (VNS), 249–51
- Valium. *See* benzodiazepines; diazepam
- Vgontzas, Alexandros, 128–29
- vibration, 195
- Vioxx, 148
- viral infections, 229
- CFS and, 57–58, 72–73, 245–46
 - immune system response to, 222–23, 232–33, 246
 - mononucleosis as, 35–36
 - viruses, reactivated, 36–38
- vision. *See* eyes and vision
- vitamin B₁₂, for fatigue, 141–42
- walking, 166, 172–81, 205
- weight gain, 113, 134, 204, 209
- weight loss, 99, 152, 204–5, 208–9
- wellness mantra, 178–79
- wellness therapy, 3–4, 170–72
- women. *See* gender
- worry, 7, 48
- worthlessness, 99, 102, 107
- Xanax. *See* benzodiazepines
- X-ray study, of lower bowel, 42
- Xyrem, 248
- yoga, 201–3
- yo-yo effect, in energy budgeting, 161, 163, 165–67, 172, 174, 179–80
- zaleplon (Sonata), 156
- zolpidem (Ambien), 156
- zonisamide (Zonegran), 152